Discovery of benzoylisoindolines as a novel class of potent, selective and orally active GlyT1 inhibitors.

Benzoylisoindolines were discovered as a novel structural class of GlyT1 inhibitors. SAR studies and subsequent lead optimization efforts focused primarily on addressing hERG liability and on improving in vivo efficacy resulted in the identification of potent GlyT1 inhibitors displaying excellent selectivity and in vivo PD and PK profiles.

[1]  Z. Rankovic,et al.  Medicinal chemistry of hERG optimizations: Highlights and hang-ups. , 2006, Journal of medicinal chemistry.

[2]  C. Parsons,et al.  Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. , 1998, Pharmacological reviews.

[3]  D. Javitt.  Glycine transport inhibitors for the treatment of schizophrenia: symptom and disease modification. , 2009, Current opinion in drug discovery & development.

[4]  E. Pinard,et al.  Discovery of benzoylpiperazines as a novel class of potent and selective GlyT1 inhibitors. , 2008, Bioorganic & medicinal chemistry letters.

[5]  Alexander Alanine,et al.  Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. , 2010, Journal of medicinal chemistry.

[6]  C. Sur,et al.  Glycine transporter 1 inhibitors and modulation of NMDA receptor-mediated excitatory neurotransmission. , 2007, Current drug targets.

[7]  Y. Shim,et al.  A Convenient Preparation of Halide-Containing Quinolinic and Cinchomeronic Acid , 2002 .

[8]  C. Lindsley,et al.  Progress in the preparation and testing of glycine transporter type-1 (GlyT1) inhibitors. , 2006, Current topics in medicinal chemistry.

[9]  C. Sur,et al.  Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors. , 2010, Current topics in medicinal chemistry.

[10]  C. Christoffersen,et al.  The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors. , 2004, Bioorganic & medicinal chemistry letters.

[11]  Daniel C Javitt,et al.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions. , 2007, International review of neurobiology.

[12]  V. Ognyanov,et al.  ALX 5407: a potent, selective inhibitor of the hGlyT1 glycine transporter. , 2001, Molecular pharmacology.

[13]  K Gubernator,et al.  Physicochemical high throughput screening: parallel artificial membrane permeation assay in the description of passive absorption processes. , 1998, Journal of medicinal chemistry.

[14]  B. Kee,et al.  Potentiation of the NMDA receptor in the treatment of schizophrenia: focused on the glycine site , 2007, European Archives of Psychiatry and Clinical Neuroscience.

[15]  K. Hashimoto.  Glycine Transport Inhibitors for the Treatment of Schizophrenia , 2010, The open medicinal chemistry journal.

[16]  G. Walker,et al.  Discovery and SAR of org 24598-a selective glycine uptake inhibitor. , 2001, Bioorganic & medicinal chemistry letters.

[17]  P. Mátyus,et al.  Glycine transporter type-1 and its inhibitors. , 2006, Current medicinal chemistry.